Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Foss Abrahamsen

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|June 10, 1985
[Lymphogranulomatosis. Current views]A Foss Abrahamsen, R Følling Elgjo, H Høst
Cancer Treatment Reports|December 1, 1987
Mitoxantrone in the treatment of patients with non-Hodgkin's LymphomaA Foss-Abrahamsen, P Lenner, M Hedenus, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 1998
Hodgkin's disease in a national and hospital population: trends over 20 yearsA Foss Abrahamsen, T Egeland, S Hansen, et al.
Scandinavian Journal of Haematology|May 1, 1985
3H-thymidine uptake in B cell lymphomas--relationship to treatment response and survivalS Kvaløy, P F Marton, O Kaalhus, et al.
International Journal of Cancer|February 15, 1984
Transferrin receptor and B-lymphoblast antigen--their relationship to DNA synthesis, histology and survival in B-cell lymphomasS Kvaløy, R Langholm, O Kaalhus, et al.
Scandinavian Journal of Immunology|November 1, 1981
Immunological subsets in human B-cell lymphomasT Godal, T Lindmo, P F Marton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2002
Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up timeA Foss Abrahamsen, A Andersen, O Nome, et al.
European Journal of Haematology|February 1, 1997
Systemic pneumococcal disease after staging splenectomy for Hodgkin's disease 1969-1980 without pneumococcal vaccine protection: a follow-up study 1994A Foss Abrahamsen, E A Høiby, E Hannisdal, et al.
International Journal of Cancer|May 15, 1987
The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomasH Holte, C D Davies, S Kvaløy, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|June 10, 1985
[Lymphogranulomatosis. Current views]A Foss Abrahamsen, R Følling Elgjo, H Høst
Cancer Treatment Reports|December 1, 1987
Mitoxantrone in the treatment of patients with non-Hodgkin's LymphomaA Foss-Abrahamsen, P Lenner, M Hedenus, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 1998
Hodgkin's disease in a national and hospital population: trends over 20 yearsA Foss Abrahamsen, T Egeland, S Hansen, et al.
Scandinavian Journal of Haematology|May 1, 1985
3H-thymidine uptake in B cell lymphomas--relationship to treatment response and survivalS Kvaløy, P F Marton, O Kaalhus, et al.
International Journal of Cancer|February 15, 1984
Transferrin receptor and B-lymphoblast antigen--their relationship to DNA synthesis, histology and survival in B-cell lymphomasS Kvaløy, R Langholm, O Kaalhus, et al.
Scandinavian Journal of Immunology|November 1, 1981
Immunological subsets in human B-cell lymphomasT Godal, T Lindmo, P F Marton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2002
Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up timeA Foss Abrahamsen, A Andersen, O Nome, et al.
European Journal of Haematology|February 1, 1997
Systemic pneumococcal disease after staging splenectomy for Hodgkin's disease 1969-1980 without pneumococcal vaccine protection: a follow-up study 1994A Foss Abrahamsen, E A Høiby, E Hannisdal, et al.
International Journal of Cancer|May 15, 1987
The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomasH Holte, C D Davies, S Kvaløy, et al.
Pageof 1